KBC Group’s BridgeBio Pharma BBIO Stock Holding History

KBC Group’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$312K	Hold	4,743	–	–	﹤0.01%	878
2026 Q2	$353K	Hold	4,743	–	–	﹤0.01%	865
2026 Q1	$352K	Buy	4,743 +548	+13%	+$39.7K	﹤0.01%	840
2025 Q4	$321K	Hold	4,195	–	–	﹤0.01%	781
2025 Q3	$218K	Hold	4,195	–	–	﹤0.01%	871
2025 Q2	$181K	Sell	4,195 -1,905	-31%	-$69.3K	﹤0.01%	905
2025 Q1	$211K	Buy	6,100 +153	+3%	+$5.16K	﹤0.01%	1038
2024 Q4	$163K	Buy	5,947 +2,456	+70%	+$63.5K	﹤0.01%	1247
2024 Q3	$89K	Buy	3,491 +649	+23%	+$17K	﹤0.01%	1359
2024 Q2	$72K	Hold	2,842	–	–	﹤0.01%	1386
2024 Q1	$88K	Buy	2,842 +887	+45%	+$30.2K	﹤0.01%	1190
2023 Q4	$79K	Sell	1,955 -256	-12%	-$7.69K	﹤0.01%	1209
2023 Q3	$58K	Buy	+2,211	New	+$62.7K	﹤0.01%	1322

Other funds holding BBIO

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Kohlberg Kravis Roberts & Co New York $5.04B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

KBC Group's BBIO Position: Q3 2026 in Review

KBC Group held its BridgeBio Pharma (BBIO) position steady in Q3 2026 at 4,743 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #878.

KBC Group first reported a position in BBIO in Q3 2023 and has held it in 13 quarters since. The position peaked at $353K in Q2 2026. 348 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

KBC Group held 4,743 shares of BridgeBio Pharma worth $312K as of Q3 2026.
KBC Group left its BridgeBio Pharma share count unchanged in Q3 2026.
BridgeBio Pharma made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #878 holding.
KBC Group first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 13 quarters since.
KBC Group's BridgeBio Pharma position peaked at $353K in Q2 2026.
348 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.